Last $0.03 USD
Change Today -0.0024 / -7.38%
Volume 18.0K
As of 8:10 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

alseres pharmaceuticals inc (ALSE) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/1/13 - $0.06
52 Week Low
12/31/13 - $0.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

alseres pharmaceuticals inc (ALSE) Related Businessweek News

No Related Businessweek News Found

alseres pharmaceuticals inc (ALSE) Details

Alseres Pharmaceuticals, Inc., a biotechnology company, together with its subsidiaries, focuses on developing therapeutic and diagnostic products primarily for disorders in the central nervous system. The company’s clinical product candidate, Altropane, is a molecular imaging program, which focuses on the diagnosis of Parkinsonian syndromes, including Parkinson’s disease, and dementia with lewy bodies. It has a license agreement with Navidea Biopharmaceuticals, Inc. to research, develop, and commercialize Altropane, an Iodine-123 radiolabeled imaging agent for the diagnosis of Parkinson’s disease and movement disorders. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

3 Employees
Last Reported Date: 04/10/14
Founded in 1972

alseres pharmaceuticals inc (ALSE) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: $401.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $267.8K
Compensation as of Fiscal Year 2013.

alseres pharmaceuticals inc (ALSE) Key Developments

Alseres Pharmaceuticals, Inc. announced delayed 10-Q filing

On 05/16/2014, Alseres Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Alseres Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt

Alseres Pharmaceuticals, Inc. filed its 10-K on Apr 10, 2014 for the period ending Dec 31, 2013. In this report its auditor, McGladrey LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Alseres Pharmaceuticals, Inc. announced delayed annual 10-K filing

On 03/31/2014, Alseres Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALSE:US $0.03 USD -0.0024

ALSE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALSE.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALSE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALSERES PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at